INTRODUCTION: Overexpression of epidermal growth factor receptor (EGFR) has been described in several solid tumors including bladder cancer. Transforming growth factor alpha (TGFα) is frequently deregulated in neoplastic cells and plays a role in the development of bladder cancer. TGFα-EGFR ligand-receptor combination constitutes an important event in multistep tumorigenesis. METHODS: This study was done on 30 bladder biopsies from patients with urothelial carcinoma, 15 with squamous cell carcinoma, 10 with cystitis and 5 normal control bladder specimens. All were immuohistochemically stained with EGFR and TGFα antibodies. RESULTS: EGFR and TGFα were over-expressed in higher grades and late stages of bladder cancer. Moreover, they show higher expression in squamous cell carcinoma compared to urothelial carcinoma and in schistosomal associated lesions than in non-schistosomal associated lesions. CONCLUSION: EGFR and TGFα could be used as prognostic predictors in early stage and grade of bladder cancer cases, especially those with schistosomal association. In addition they can help in selecting patients who can get benefit from anti-EGFR molecular targeted therapy.
INTRODUCTION: Overexpression of epidermal growth factor receptor (EGFR) has been described in several solid tumors including bladder cancer. Transforming growth factor alpha (TGFα) is frequently deregulated in neoplastic cells and plays a role in the development of bladder cancer. TGFα-EGFR ligand-receptor combination constitutes an important event in multistep tumorigenesis. METHODS: This study was done on 30 bladder biopsies from patients with urothelial carcinoma, 15 with squamous cell carcinoma, 10 with cystitis and 5 normal control bladder specimens. All were immuohistochemically stained with EGFR and TGFα antibodies. RESULTS:EGFR and TGFα were over-expressed in higher grades and late stages of bladder cancer. Moreover, they show higher expression in squamous cell carcinoma compared to urothelial carcinoma and in schistosomal associated lesions than in non-schistosomal associated lesions. CONCLUSION:EGFR and TGFα could be used as prognostic predictors in early stage and grade of bladder cancer cases, especially those with schistosomal association. In addition they can help in selecting patients who can get benefit from anti-EGFR molecular targeted therapy.
Authors: Charles C Guo; Enrique Gomez; Pheroze Tamboli; Jolanta E Bondaruk; Ashish Kamat; Roland Bassett; Colin P Dinney; Bogdan A Czerniak Journal: Hum Pathol Date: 2009-05-19 Impact factor: 3.466
Authors: Ashley S Felix; Amr S Soliman; Hussein Khaled; Mohamed S Zaghloul; Mousumi Banerjee; Manal El-Baradie; Mohamed El-Kalawy; Alaa A Abd-Elsayed; Kadry Ismail; Ahmed Hablas; Ibrahim A Seifeldin; Mohamed Ramadan; Mark L Wilson Journal: Cancer Causes Control Date: 2008-01-10 Impact factor: 2.506
Authors: Esmail M Al-Ezzi; Zachary W Veitch; Samer H Salah; Theodorus H Van der Kwast; Tracy L Stockley; Shamini Selvarajah; Tong Zhang; Srikala S Sridhar; Adrian G Sacher; Nazanin Fallah-Rad; Girish S Kulkarni; Alexandre R Zlotta; Antonio Finelli; Aaron R Hansen Journal: PLoS One Date: 2021-12-01 Impact factor: 3.240